Smith Salley Wealth Management Has $2.46 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Smith Salley Wealth Management lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,393 shares of the medical research company’s stock after buying an additional 377 shares during the period. Smith Salley Wealth Management’s holdings in IQVIA were worth $2,463,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Park Place Capital Corp acquired a new position in IQVIA during the 3rd quarter worth approximately $28,000. Versant Capital Management Inc grew its stake in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the second quarter worth $27,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the 2nd quarter valued at $29,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the 2nd quarter valued at $32,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 1.4 %

Shares of IQVIA stock opened at $214.63 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The stock has a 50 day moving average price of $237.63 and a two-hundred day moving average price of $230.49. The stock has a market capitalization of $39.11 billion, a PE ratio of 29.32, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on IQV. Royal Bank of Canada started coverage on IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 target price for the company. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Tuesday, October 22nd. Redburn Atlantic initiated coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Truist Financial cut their price target on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a report on Monday, October 14th. Finally, Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $267.27.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.